Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;107(4):694-708.
doi: 10.1111/j.1360-0443.2011.03473.x. Epub 2011 Jul 22.

Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials

Dennis M Donovan  1 , George E Bigelow, Gregory S Brigham, Kathleen M Carroll, Allan J Cohen, John G Gardin, John A Hamilton, Marilyn A Huestis, John R Hughes, Robert Lindblad, G Alan Marlatt, Kenzie L Preston, Jeffrey A Selzer, Eugene C Somoza, Paul G Wakim, Elizabeth A Wells
Affiliations

Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials

Dennis M Donovan et al. Addiction. 2012 Apr.

Abstract

Aims: Clinical trials test the safety and efficacy of behavioral and pharmacological interventions in drug-dependent individuals. However, there is no consensus about the most appropriate outcome(s) to consider in determining treatment efficacy or on the most appropriate methods for assessing selected outcome(s). We summarize the discussion and recommendations of treatment and research experts, convened by the US National Institute on Drug Abuse, to select appropriate primary outcomes for drug dependence treatment clinical trials, and in particular the feasibility of selecting a common outcome to be included in all or most trials.

Methods: A brief history of outcomes employed in prior drug dependence treatment research, incorporating perspectives from tobacco and alcohol research, is included. The relative merits and limitations of focusing on drug-taking behavior, as measured by self-report and qualitative or quantitative biological markers, are evaluated.

Results: Drug-taking behavior, measured ideally by a combination of self-report and biological indicators, is seen as the most appropriate proximal primary outcome in drug dependence treatment clinical trials.

Conclusions: We conclude that the most appropriate outcome will vary as a function of salient variables inherent in the clinical trial, such as the type of intervention, its target, treatment goals (e.g. abstinence or reduction of use) and the perspective being taken (e.g. researcher, clinical program, patient, society). It is recommended that a decision process, based on such trial variables, be developed to guide the selection of primary and secondary outcomes as well as the methods to assess them.

PubMed Disclaimer

Conflict of interest statement

Declarations of interest

None.

Figures

Figure 1
Figure 1
Heuristic model of factors to be considered in selecting outcome measures in drug dependence treatment clinical trials. TLFB: timeline follow-back
See this image and copyright information in PMC

Comment in

References

    1. Wells EA, Saxon AJ, Calsyn DA, Jackson TR, Donovan DM. Study results from the Clinical Trials Network’s first 10 years: where do they lead? J Subst Abuse Treat. 2010;38:S14–30. - PMC - PubMed
    1. Wells EA, Hawkins JD, Catalano RF., Jr Choosing drug use measures for treatment outcome studies. I. The influence of measurement approach on treatment results. Int J Addict. 1988;23:851–73. - PubMed
    1. Wells EA, Hawkins JD, Catalano RF., Jr Choosing drug use measures for treatment outcome studies. II. Timing baseline and follow-up measurement. Int J Addict. 1988;23:875–85. - PubMed
    1. Van den Brink W, Montgomery SA, Van Ree JM, van Zwieten-Boot BJ On behalf of the Consensus Committee. ECNP Consensus Meeting March 2003: guidelines for the investigation of efficacy in substance use disorders. Eur Neuropsychopharmacol. 2006;16:224–30. - PubMed
    1. Marsden J, Nizzoli U, Corbelli C, Margaron H, Torres M, Prada De Castro I, et al. New European instruments for treatment outcome research: reliability of the maudsley addiction profile and treatment perceptions questionnaire in Italy, Spain and Portugal. Eur Addict Res. 2000;6:115–22. - PubMed